In view of these findings, we also obtained a novel potent dual CK2/PIM-1 inhibitor, namely 3-(4,5,6,7-tetrabromo-2-methyl-1H-1,3-benzodiazol-1-yl)propan-1-ol (N1-PrOH-TBBi), which, after functionalization into its corresponding acetyl prodrug, turned out to be a very promising anticancer agent toward breast cancer cell lines [40]. Here, PIM1 is linked to breast cancer.